Med College Wisconsin - Medin MM vs BCell

Clustergrammer Heatmap
 
Download
Medin_PRM_Lumos_180906_LFQ_Good2Go_Panorama_2019-11-01_16-09-52.sky.zip2020-02-05 22:21:39652102232,23066
Medin_PRM_Lumos_181018_Patient_LFQ_Refine_Panorama_2019-11-01_15-13-25.sky.zip2020-02-05 22:21:39621922072,23744
Medin_PRM_Lumos_190116_PatientGroup2_LFQ_Refine3_Panorama_2019-11-01_13-28-35.sky.zip2020-02-05 22:21:39561671821,97132
Mapping of the multiple myeloma cell surface N-glycoproteome and targeted validation in patient samples uncovers immunotherapy targets

  • Organism: Homo sapiens
  • Instrument: Orbitrap Fusion Lumos
  • SpikeIn: No
  • Keywords: Cell Surface Capture, PRM, Multiple Myeloma
  • Lab head: Rebekah Gundry
Abstract
Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells in the bone marrow. While recent advances in treatment for MM have improved patient outcomes, the 5-year survival rate remains ~50%. A better understanding of the MM cell surface proteome could facilitate development of new therapies and assist in stratification and monitoring of patient outcomes. In this study, we used a mass spectrometry (MS)-based discovery approach termed cell surface capture (CSC) technology to map the cell surface N-glycoproteome of MM cell lines. We identified 696 MM cell surface N-glycoproteins by CSC and developed targeted detection assays for 73 proteins of interest. We then applied targeted MS analysis to primary MM patient samples, revealing 30 proteins with significantly higher abundance in patient MM cells than controls. Nine of these proteins were identified as potential immunotherapeutic targets, including five that are already under investigation for other cancers. These data will be a valuable resource in the development of biomarkers and therapeutics, and we anticipate that our targeted MS assays will have clinical benefit for the diagnosis, stratification, and treatment of MM patients.
Created on 2/5/20, 10:33 PM

This data is available under the CC BY 4.0 license.